Polycyclo-carbocyclic Ring System Having At Least Three Cyclos Patents (Class 546/285)
-
Publication number: 20110190354Abstract: Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).Type: ApplicationFiled: July 15, 2009Publication date: August 4, 2011Inventors: Hideyuki Takeuchi, Akio Suzumura
-
Publication number: 20110190505Abstract: This disclosure relates to compounds, reagents, and methods useful in the synthesis of aryl fluorides, for example, in the preparation of 18F labeled radiotracers. For example, this disclosure provides universal “locked” aryl substituents that result in StereoElectronic Control of Unidirectional Reductive Elimination (SECURE) from diaryliodonium salts. The reagents and methods provided herein may be used to access a broad range of compounds, including aromatic compounds, heteroaromatic compounds, amino acids, nucleotides, and synthetic compounds.Type: ApplicationFiled: February 4, 2011Publication date: August 4, 2011Inventor: Stephen DiMagno
-
Patent number: 7989467Abstract: The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromosome 17 (a form of Parkinson's disease), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain neuropathologies including Alzheimer's disease linked to a mutation in the Tau protein, muscle atorphy which affects the SMN (Survival of Motor Neuron) gene, depression linked to a serotonin splicing impairment, and certain cancers in which the global splicing process is affected (e.g. breast cancer, colon cancer and certain lymphomas), as well as viral diseases such as AIDS.Type: GrantFiled: September 6, 2004Date of Patent: August 2, 2011Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Montpellier II, Institut CurieInventors: Jamal Tazi, Johann Soret, Philippe Jeanteur, David Grierson, Christian Rivalle, Emile Bisagni, Chi Hung Nguyen
-
Patent number: 7960039Abstract: An amino compound for an organic light-emitting device of general formula [1]: wherein X1 is bonded to the pair of fluorenyl groups at meta-positions to each other and is substituted or unsubstituted aromatic ring, fused polycyclic ring, or heterocyclic ring; Y1 and Y2 are each substituted or unsubstituted alkyl, aryl, or heterocyclic and are the same or different; Z1 to Z4 are each hydrogen, halogen, or substituted or unsubstituted alkyl, aralkyl, alkenyl, alkynyl, alkoxy, aryl, or heterocyclic and are the same or different; R1 to R4 are each hydrogen, halogen, or substituted or unsubstituted alkyl, aryl, or heterocyclic and are the same or different; a and d are each 1 to 4; and b and c are each 1 to 3.Type: GrantFiled: March 23, 2007Date of Patent: June 14, 2011Assignee: Canon Kabushiki KaishaInventors: Shigemoto Abe, Akihiro Senoo, Naoki Yamada, Chika Negishi
-
Publication number: 20110077160Abstract: Compounds having the following generic formula are disclosed.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Inventors: Nneka T. Breaux, Michael R. Loso, Timothy C. Johnson, Jonathan M. Babcock, Benjamin M. Nugent, Timothy P. Martin, Annette V. Brown, Ronald Ross, JR., William C. Lo, Matthias S. Ober
-
Publication number: 20110077251Abstract: The invention relates to 17? lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.Type: ApplicationFiled: August 16, 2010Publication date: March 31, 2011Inventors: Christophe Moinet, Bingcan Liu, Liliane Halab, Nathalie Turcotte, Real Denis, Carl Poisson, Paul Nguyen-Ba, Monica Bubenik, Laval Chan Chun Kong
-
Publication number: 20110056562Abstract: A compound represented by the following formula (I), and a photoelectric conversion device containing the compound: wherein Z1 is a ring containing two carbon atoms and represents a 5-membered ring, a 6-membered ring or a condensed ring containing at least either a 5-membered ring or a 6-membered ring, each of L1, L2 and L3 independently represents an unsubstituted methine group or a substituted methine group, n represents an integer of 0 or more, each of R1, R2, R3, R4, R5 and R6 independently represents a hydrogen atom or a substituent, R1 and R2, R2 and R3, R4 and R5, or R5 and R6 may be combined with each other to form a ring, and each of R21 and R22 independently represents a substituted aryl group, an unsubstituted aryl group, a substituted heteroaryl group or an unsubstituted heteroaryl group, provided that the case where both R21 and R22 are an unsubstituted phenyl group is excluded.Type: ApplicationFiled: September 8, 2010Publication date: March 10, 2011Applicant: FUJIFILM CORPORATIONInventors: Mitsumasa HAMANO, Katsuyuki YOFU, Tetsuro MITSUI, Kimiatsu NOMURA
-
Patent number: 7893282Abstract: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.Type: GrantFiled: October 10, 2007Date of Patent: February 22, 2011Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Laura Honeyman
-
Publication number: 20110039853Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 19, 2008Publication date: February 17, 2011Inventor: Soren Ebdrup
-
Patent number: 7888355Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: GrantFiled: August 11, 2010Date of Patent: February 15, 2011Assignee: Burnham Institute for Medical ResearchInventors: Ze′ev A. Ronai, Anindita Bhoumik, Nicholas D. P. Cosford, Russell Dahl
-
Publication number: 20110021480Abstract: Substituted steroid compounds which represent selective inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17?-estradiol concentration.Type: ApplicationFiled: September 28, 2010Publication date: January 27, 2011Applicant: Solvay Pharmaceuticals GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Publication number: 20110003852Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 18, 2008Publication date: January 6, 2011Inventor: Soren Ebdrup
-
Publication number: 20110003856Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 18, 2008Publication date: January 6, 2011Inventor: Soren Ebdrup
-
Publication number: 20100327270Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material in the emitting layer and/or as electron-transport material.Type: ApplicationFiled: February 13, 2009Publication date: December 30, 2010Applicant: Merck Patent GmbHInventors: Arne Buesing, Holger Heil, Philipp Stoessel
-
Publication number: 20100331366Abstract: Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 19, 2008Publication date: December 30, 2010Applicant: High Point Pharmaceuticals ,LLCInventor: Soren Ebdrup
-
Publication number: 20100320451Abstract: A fused aromatic ring derivative shown by the following formula (1): wherein Ra and Rb are independently a hydrogen atom or a substituent, m and n are independently an integer of 1 to 13, and when m and n are two or more, Ras and Rbs may be independently the same or different, and L1 is a single bond or a substituted or unsubstituted divalent linking group, provided that the fused aromatic ring derivative shown by the formula (1) does not have an anthracene ring.Type: ApplicationFiled: November 10, 2008Publication date: December 23, 2010Inventor: Masahiro Kawamura
-
Publication number: 20100305326Abstract: Disclosed herein are methods related to drug development. The methods typically include steps whereby two chemical fragments are identified as binding to a target protein and subsequently the two chemical fragments are joined to create a new chemical entity that binds to the target protein.Type: ApplicationFiled: June 2, 2010Publication date: December 2, 2010Applicant: Marquette UniversityInventor: Daniel S. Sem
-
Publication number: 20100305129Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Applicant: Burnham Institute for Medical ResearchInventors: Zéev A. Ronai, Anindita Bhoumik, Nicholas D.P. Cosford, Russell Dahl
-
Publication number: 20100292215Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.Type: ApplicationFiled: March 27, 2007Publication date: November 18, 2010Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Soren Ebdrup, Henrik Sune Andersen
-
Publication number: 20100273801Abstract: The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications.Type: ApplicationFiled: June 6, 2007Publication date: October 28, 2010Applicant: Valition teknillinen tutikimuskeskusInventors: Jari Yli-Kauhaluoma, Salme Koskimies, Sami Alakurtti, Taru Mäkelä, Päivi Tammela
-
Publication number: 20100266509Abstract: Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: April 9, 2008Publication date: October 21, 2010Applicant: H. Lindbeck A/SInventors: David C. Ihle, Qin Guo, Kevin Hodgetts, Jun Yuan
-
Publication number: 20100261911Abstract: An object of the present invention is to find a novel pharmacological action of a urea compound having a structure represented by the general formula [I]. The urea compound having a structure represented by the general formula [I] or a salt thereof has an excellent therapeutic effect on a TRPV1-mediated disease. In the formula, A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and R2 and R3 are the same or different and represent a hydrogen atom or a lower alkyl group which may be substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group, or an aryl group.Type: ApplicationFiled: October 16, 2008Publication date: October 14, 2010Inventors: Kenji Oki, Fumio Tsuji, Chikako Setoguchi, Iwao Seki, Masaaki Murai, Minoru Sasano
-
Publication number: 20100187978Abstract: The present invention relates to a material for an organic electro-optical device and an organic electro-optical device including the same. More particularly, the present invention relates to a material having thermal stability of a glass transition temperature of 120° C. or more and a thermal decomposition temperature of 450° C. or more, and being capable of providing an organic electro-optical device having high efficiency and a long life-span due to less crystallization and improved amorphous properties in a material for an organic electro-optical device. The material for an organic electro-optical device can be used singularly or as a host material in combination with a dopant, and includes an asymmetric fluorene derivative compound. An organic electro-optical device including the material for an organic electro-optical device is also provided.Type: ApplicationFiled: May 28, 2008Publication date: July 29, 2010Applicant: CHEIL INDUSTRIES INC.Inventors: Eun Sun Yu, Nam Soo Kim, Young Hoon Kim, Mi Young Chae
-
Publication number: 20100190795Abstract: The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.Type: ApplicationFiled: June 6, 2007Publication date: July 29, 2010Applicant: Valtion Teknillinen tutkimuskeskusInventors: Jari Yli-Kauhaluoma, Sami Alakurtti, Jaana Minkkinen, Nina Sarcerdoti-Sierra, Charles L. Jaffe, Tuomo Heiska
-
Publication number: 20100187505Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.Type: ApplicationFiled: April 29, 2008Publication date: July 29, 2010Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
-
Publication number: 20100160263Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: November 12, 2009Publication date: June 24, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy Nagavelli, Karen Stepleton, Tad Warchol, Paul Sheahan
-
NOVEL ORGANOMETALLIC COMPLEXES WHICH EMIT IN THE RED TO GREEN SPECTRAL REGION AND THEIR USE IN OLEDS
Publication number: 20100127215Abstract: Organometallic complexes which bear at least one ligand which has a unit having a triplet energy of at least 22 000 cm?1, a process for preparing the organometallic complexes, a mixture comprising at least one inventive organometallic complex, the use of the organometallic complexes or of the mixture in organic light-emitting diodes, the organometallic complexes preferably being used as emitter materials, and specific nitrogen- or phosphorus-substituted triphenylene derivatives and a process for their preparation.Type: ApplicationFiled: April 4, 2008Publication date: May 27, 2010Applicant: BASF SEInventors: Herbert Friedrich Boerner, Hans-Peter Loebl, Josef Salbeck, Elena Popova -
Publication number: 20100069444Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: July 20, 2009Publication date: March 18, 2010Applicant: PFIZER, INC.Inventor: Paul V. Rucker
-
Patent number: 7667043Abstract: Aromatic and heteroaromatic molecular structures with controllable electron conducting properties are derived from the incorporation of electron active substituents in selective positions. Such compounds can form self-assembled layers on metal or other substrates, and can be used in molecular scaled opto-electronic devices including field-effect transistors, light-emitting diodes and photovoltaic cells.Type: GrantFiled: March 20, 2006Date of Patent: February 23, 2010Assignee: E.I. du Pont de Nemours and CompanyInventors: Ross Getty, Simona Percec
-
Publication number: 20100025661Abstract: The subject of the present invention is to provide an emission material which contributes to high emission efficiency, low drive voltage, excellent heat resistance and long life in an organic electroluminescent device, particularly an emission material which is excellent in emission of blue color. Further, the subject is to provide an organic electroluminescent device using the above emission material. The above subjects can be achieved by an emission material represented by Formula (1) and an organic electroluminescent device comprising the same. wherein R1 to R7 are independently hydrogen, alkyl or cycloalkyl; Ar1 is one selected from the group consisting of non-condensed aryl having 6 to 50 carbon atoms, 2-naphthyl, 9-phenanthryl, 6-chrysenyl, 2-triphenylenyl, 2-fluorenyl, 9-carbazolyl, 2-thienyl and 2-benzothienyl; and Ar2 and Ar3 are independently non-condensed aryl having 6 to 50 carbon atoms, condensed aryl having 10 to 50 carbon atoms or heteroaryl having 2 to 50 carbon atoms.Type: ApplicationFiled: June 24, 2005Publication date: February 4, 2010Inventors: Guofang Wang, Manabu Uchida, Youhei Ono
-
Publication number: 20090306022Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
NOVEL POLYMORPH OF (5-AMINO-6-METHOXY-3-PYRIDINCARBONYL) CARBAMIC ACID 2-(S)-HYDROXYMUTILIN 14-ESTER
Publication number: 20090291987Abstract: The present invention relates to a novel polymorph, to processes for the preparation of the polymorph and to the use of the polymorph in medicine, particularly antibacterial therapy.Type: ApplicationFiled: December 9, 2005Publication date: November 26, 2009Inventors: Steven Geoffrey Aitken, Steven Dabbs, Eric Hunt -
Patent number: 7612103Abstract: Compounds of formula wherein R1 and R1? are hydrogen or deuterium, R2, R3 and R4 are hydrogen or deuterium, R5 is the residue of an amino acid, X is S or N-ALK, is piperidinyl or tetrahydropyridinyl, ALK is (C1-4)alkyl, and R6 is hydrogen, hydroxy or (C2-12)acyloxy, and their use as antimicrobials.Type: GrantFiled: July 23, 2003Date of Patent: November 3, 2009Assignee: Nabriva Therapeutics AGInventors: Heinz Berner, Gabriele Kerber
-
Patent number: 7585574Abstract: Provided are a pyrene derivative of a specified structure and an organic electroluminescence device including an organic thin film layer formed of one or multiple layers including at least a light emitting layer, the organic thin film layer being interposed between a cathode and an anode, in which at least one layer of the organic thin film layer contains the pyrene derivative alone or as a component of mixture. Thus, there are provided an organic electroluminescence device capable of obtaining long-life blue light emission with high luminous efficiency and a novel pyrene derivative for realization thereof.Type: GrantFiled: October 29, 2007Date of Patent: September 8, 2009Assignee: Idemitsu Kosan Co., Ltd.Inventors: Mitsunori Ito, Mineyuki Kubota
-
Publication number: 20090221591Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.Type: ApplicationFiled: March 2, 2006Publication date: September 3, 2009Applicant: Universitat Des SaarlandesInventors: Rolf W. Hartmann, Marieke Voets, Ursula Müller-Vieira
-
Publication number: 20090197844Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.Type: ApplicationFiled: December 12, 2006Publication date: August 6, 2009Inventor: Lee Roy Morgan
-
Publication number: 20090160326Abstract: An organic EL element having one or a plurality of organic layers including a light emitting layer between a pair of electrodes is arranged such that at least one layer of the above-mentioned organic layers contains a compound as expressed by the following general formula (1) independently or as a mixture. (where, R1-R7 are selected from the group consisting of hydrogen, an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkoxy group, and an aryloxy group, and they may be the same groups or the groups different from one another, and A1-A3 are selected from the group consisting of a phenyl group which is either substituted or unsubstituted and a 5 or 6 member heterocyclic ring group which is either substituted or unsubstituted, and they may be the same groups or the groups different from one another.Type: ApplicationFiled: December 22, 2008Publication date: June 25, 2009Applicant: Yamagata Promotional Organization for Industrial TechnologyInventors: Atsushi ODA, Masato KIMURA
-
Patent number: 7547714Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: January 31, 2008Date of Patent: June 16, 2009Assignee: Pfizer, Inc.Inventor: Hengmiao (Henry) Cheng
-
Publication number: 20090105203Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.Type: ApplicationFiled: October 16, 2007Publication date: April 23, 2009Applicant: Myriad Genetics, IncorporatedInventors: Kraig M. Yager, Esther Arranz Plaza, Dange Vijay Kumar, In Chul Kim
-
Publication number: 20090088570Abstract: An organic electroluminescent device, which has, between a pair of electrodes, at least one organic layer including a light-emitting layer, in which the organic layer contains a specific tetraphenylene compound, and in which the light-emitting layer contains a phosphorescent material; and a specific tetraphenylene compound that can be used in the device.Type: ApplicationFiled: November 20, 2008Publication date: April 2, 2009Applicant: FUJIFILM CORPORATIONInventors: Jun OGASAWARA, Tatsuya Igarashi, Satoshi Sano
-
Publication number: 20090054438Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: ApplicationFiled: August 15, 2008Publication date: February 26, 2009Applicant: Burnham Institute for Medical ResearchInventors: Ze'ev A. Ronai, Anindita Bhoumik, Nicholas D.P. Cosford, Russell Dahl
-
Publication number: 20090042929Abstract: There is provided a compound having Formula (I) R1-Z-R2 wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(?O)—CR3R4—X—(CR5R6)n-, wherein X is selected from NR7, S, O, S?O, and S(?O)2, wherein n is 0 or 1 and/or (c) R1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR8R9)p-NR10—S(?O)2—(CR11R12)q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR13R14)V—Y—(CR15R16)W— where Y is a heteroaryl group in which a bond in the heteroaryl ring is a iType: ApplicationFiled: March 23, 2006Publication date: February 12, 2009Applicant: Sterix LimitedInventors: Nigel Vicker, Xiangdong Su, Fabienne Pradaux, Michael John Reed, Barry Victor Lloyd Potter
-
Publication number: 20090033210Abstract: To provide a novel fluoranthene derivative and an organic light emitting device having the fluoranthene derivative.Type: ApplicationFiled: April 19, 2007Publication date: February 5, 2009Applicant: CANON KABUSHIKI KAISHAInventors: Akihito Saitoh, Keiji Okinaka, Satoshi Igawa, Jun Kamatani, Naoki Yamada, Masashi Hashimoto, Masanori Muratsubaki, Takao Takiguchi, Akihiro Senoo, Shinjiro Okada, Minako Nakasu
-
Publication number: 20090026930Abstract: An aromatic compound represented by Formula 1 below and an organic light-emitting diode including the same: M1-(B)n-M2 ??(1) The aromatic compound has excellent thermal stability and emission characteristics. Thus, the organic light-emitting diode employing the aromatic compound can exhibit a low driving voltage, high efficiency, and high brightness.Type: ApplicationFiled: March 28, 2008Publication date: January 29, 2009Inventors: Dong-woo Shin, Byoung-ki Choi, Tae-yong Noh, O-hyun Kwon, Myeong-suk Kim, Yu-jin Kim, Eun-sil Han, Woon-jung Paek
-
Publication number: 20080287499Abstract: Disclosed is a series of N-deacetylthiocolchicine derivatives of formula I in which: the linker is a bivalent straight or branched C1-C8 alkyl residue, C3-C8 cycloalkyl, a phenylene or heterocyclic C4-C6 ring; the G1 and G2 junctions, which can be the same or different, are —CO—, —CONH—, —CR2— groups in which R2 is hydrogen or a straight C1-C4 alkyl residue, or the G1-linker-G2 group is the —CO— group. The compounds of formula I have antiproliferative, antiinflammatory, antiarthritic and antiviral activity.Type: ApplicationFiled: June 19, 2008Publication date: November 20, 2008Applicant: INDENA S.P.A.Inventors: Ezio Bombardelli, Gabriele Fontana
-
Publication number: 20080188443Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: January 31, 2008Publication date: August 7, 2008Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A. DeCresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20080166593Abstract: The present invention relates to the use of certain organic compounds comprising fused aromatic compounds in organic electronic devices, in particular electroluminescent devices.Type: ApplicationFiled: March 20, 2006Publication date: July 10, 2008Inventors: Philipp Stoessel, Holger Heil, Horst Vestweber
-
Publication number: 20080153850Abstract: The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.Type: ApplicationFiled: August 29, 2005Publication date: June 26, 2008Applicant: AstraZeneca ABInventors: Rhonan Ford, Barrie Martin, Toby Thompson, Nicholas Tomkinson, Paul Willis
-
Publication number: 20080124571Abstract: Provided are a pyrene derivative of a specified structure and an organic electroluminescence device including an organic thin film layer formed of one or multiple layers including at least a light emitting layer, the organic thin film layer being interposed between a cathode and an anode, in which at least one layer of the organic thin film layer contains the pyrene derivative alone or as a component of mixture. Thus, there are provided an organic electroluminescence device capable of obtaining long-life blue light emission with high luminous efficiency and a novel pyrene derivative for realization thereof.Type: ApplicationFiled: October 29, 2007Publication date: May 29, 2008Applicant: Idemitsu Kosan Co., Ltd.Inventors: Mitsunori Ito, Mineyuki Kubota
-
Publication number: 20080111473Abstract: Provided are an anthracene derivative having a heteroaryl group containing a nitrogen-containing six-membered ring and having a specific structure and an organic electroluminescence device in which an organic thin film layer comprising a single layer or plural layers including at least a light emitting layer is interposed between a cathode and an anode, wherein at least one layer in the above organic thin film layer contains the anthracene derivative described above in the form of a single component or a mixed component. Provided are the organic electroluminescence device in which homogeneous light emission is obtained over a long period of time and which has a long lifetime and the anthracene derivative which materializes the same.Type: ApplicationFiled: November 25, 2005Publication date: May 15, 2008Applicant: IDEMITSU KOSAN CO., LTD.Inventors: Masahiro Kawamura, Chishio Hosokawa